SRx健康解决方案股份有限公司美国股票招股说明书（2026年3月6日版）

SRx HEALTH SOLUTIONS, INC.Up to 187,544,974 Shares of Common Stock This prospectus supplement updates and supplements the information contained in the prospectus dated December 31, 2025 (as maybe supplemented or amended from time to time, the “Prospectus”), which forms part of our registration statement on Form S-1 (FileNo. 333-291395), as amended, with the information contained in our Current Report on Form 8-K which was filed with the Securitiesand Exchange Commission on March 3, 2026 (the “Current Report”). Accordingly, we have attached the Current Report to this This prospectus relates to the resale from time to time by the selling stockholders named in this prospectus (collectively, the “SellingStockholders”) or their permitted transferees (after the expiration of any applicable lock-up period, assuming the satisfaction of anyapplicable vesting conditions and subject to the beneficial ownership and stock exchange limitations described herein), of up to187,552,665 shares of our common stock, par value $0.0001 per share (“Common Stock”) which consists of (a) 2,900,551 shares ofour common stock issuable upon the exercise of warrants to purchase Common Stock (“July Warrants”), purchased by certaininvestors pursuant to the Securities Purchase Agreement, dated July 7, 2025, (the “July PIPE SPA”) (the “July PIPE Financing”); (b)171,373,512 shares of our common stock which represents 200% of the 31,158,945 shares of our common stock issuable upon theconversion of shares of our Series A Convertible Preferred Stock, par value $0.0001 (the “Series A Preferred Stock”) and 54,527,811shares of our common stock issuable upon exercise of warrants to purchase Common Stock (“October Warrants”), purchased bycertain investors pursuant to the Securities Purchase Agreement, dated October 27, 2025, (the “October PIPE SPA”) (the “OctoberPIPE Financing”); (c) 491,628 shares of our common stock issuable in exchange for shares of the capital stock of SRx Health You should read the prospectus. this prospectus supplement and any additional prospectus supplement or amendment carefully beforeyou invest in our securities. Our Common Stock is listed on the NYSE American under the symbol “SRXH”. On March 2, 2026, the closing price of our CommonStock was $0.1220 per share. We are a “smaller reporting company” under applicable federal securities laws and will be subject to reduced public companyreporting requirements for so long as we remain a smaller reporting company. Investing in our securities involves a high degree of risk. Before buying any securities, you should carefully read the discussionof the risks of investing in our securities in “Risk Factors”beginning on page 8 of this prospectus and any other risk factors Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of thesecurities to be issued under this prospectus or determined if this prospectus is truthful or complete. Any representation to thecontrary is a criminal offense. The date of this prospectus supplement is March 6, 2026. FORM 8-K Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrantunder any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Item 1.01. Entry into a Material Definitive Agreement. As previously disclosed, on July 7, 2025, the Company entered into a Securities Purchase Agreement (the “Note PurchaseAgreement”) by and among the Company and certain accredited investors named therein (the “Note Investors”), pursuant to which theCompany issued and sold to the Note Investors (i) a new series of senior secured convertible notes (the “Notes”) with an aggregateoriginal principal amount of $7,650,000, subject to an original issue discount as provided in the Notes, and (ii) warrants to acquire Also as previously disclosed, on October 27, 2025, the Company entered into a Securities Purchase Agreement (the “Series A PurchaseAgreement,” and together with the Note Purchase Agreement, the “Existing Securities Purchase Agreements”) with certain accreditedinvestors named therein (the “Series A Investors,” and together with the Note Investors, the “Existing Investors”). Pursuant to theSeries A Purchase Agreement, up to 38,070 shares of the Company’s Series A convertible preferred stock, par value $0.001 per share(the “Series A Preferred Stock”), the terms of which are set forth in that certain certificate of designations for the such series ofpreferred stock (the “Existing Certificate of Designations”), and accompanying warrants (“Series A Warrants”) to purchase shares ofCommon Stock, could be purchased, in one or more closings, for an aggregate purchase price of up to $30.46 million in one or more The Company desires to enter into a securities purchase agreement (the “Ne